Samsung ’ s NeuroLogica, MaxQ AI ink collab distro deal

Samsung Electronics (LON:BC94) subsidiary NeuroLogica said today that it inked a distribution deal with MaxQ AI to integrate its artificial intelligence software with NeuroLogica’s medical imaging tech in the U.S. and EU’s acute care marketplace. Through the deal, NeuroLogica said that it will offer MaxQ’s Accipio IX, part of the AI-company’s FDA-cleared and CE Mark approved Accipio Insight intracranial hemorrhage platform intended to support acute care physicians by identifying patients with suspected intracranial hemorrhage using non-contrast head computed tomography imaging. “We are honored to partner with MaxQ and their flagship product Accipio Ix. AI is an exciting development in healthcare, and through our joint efforts, we are working to improve diagnostic accuracy and reduce time to treatment for stroke. AI has the potential to revolutionize diagnostics, and this collaboration will bring that potential into the patient’s room through our point of care CT systems,” NeuroLogica COO David Webster said in a prepared release. The Accipio IX solution will be offered as an additional tool for NeuroLogica’s OmniTom mobile 16-slice CT scanner. NeuroLogica said it will make MaxQ’s AI solutions available for integration into into its mobile stroke units as well. “Following the recent FDA clearance and CE Mark approval of Accipio Ix, our expanded partnership with Samsung NeuroLogica will further accelerate the comm...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Distribution Imaging Neurological Software / IT maxqai NeuroLogica Corp. samsung Source Type: news